Global Phase 1/2 CHORD trial investigating otoferlin gene therapy (DB-OTO) represents Regeneron’s first auditory program and is currently enrolling patients DB-OTO is part of a growing pipeline of ...

Regeneron's gene therapy DB-OTO shows significant hearing improvements in children with otoferlin-related profound hearing loss, according to trial data. Regeneron Pharmaceuticals has released updated ...

Proposed acquisition builds on existing collaboration between Decibel and Regeneron, will accelerate and further resource key gene therapy programs for hearing loss Decibel’s lead investigational gene ...

The U.S. Food and Drug Administration (FDA) has denied approval of Regeneron Pharmaceuticals’ (NASDAQ:REGN) therapy for a form of blood cancer. The New York-based biotech was seeking regulatory ...

We recently compiled a list of the 9 Best Gene Therapy Stocks to Buy Now and in this article, we discuss whether Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is the best bet in the gene therapy ...

In the CHORD trial, 10 of 11 assessed children showed improved hearing, with 3 achieving nearly normal or normal hearing levels at 24 weeks. DB-OTO was well tolerated, with no serious adverse events; ...

TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlying AATD, with Investigational New Drug filing expected by the end of the year Tessera to receive $150 ...

March 25 (Reuters) - Regeneron Pharmaceuticals (REGN.O), opens new tab said on Monday the U.S. FDA has declined approval for its blood cancer therapy for two forms of lymphoma on concerns over the ...

Regeneron CEO Leonard Schleifer elaborated on the biotech company's newest ventures with CNBC's Jim Cramer and pointed to gene therapy as especially innovative. Schleifer suggested that "associating ...

The Biomedical Advanced Research and Development Authority (BARDA) has tapped Regeneron for a next-generation COVID-19 antibody therapy, promising up to $326 million in government funds in the hope of ...